Search Result
Results for "
Ceramides
" in MedChemExpress (MCE) Product Catalog:
12
Biochemical Assay Reagents
36
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-113679
-
|
|
Telomerase
|
Metabolic Disease
Endocrinology
|
|
Ceramides Mixture is an endogenous ceramide and consists of hydroxy and non-hydroxy fatty acid-containing ceramides. Ceramides Mixture is a main lipid component of the permeability barrier in epidermis. Ceramides Mixture is involved in the regulation of growth inhibition, cell cycle arrest, and modulation of telomerase activity .
|
-
-
- HY-124177A
-
-
-
- HY-141578
-
-
-
- HY-144005
-
|
C16 PEG Ceramide (MW 2000)
|
Liposome
Autophagy
|
Cancer
|
|
C16 PEG2000 Ceramide is a polyethylene glycolylated ceramide. C16 PEG2000 Ceramide can be used for lipid carrier to delivery. C16 PEG2000 Ceramide induces autophagy. C16 PEG2000 Ceramide can be used for cancer research .
|
-
-
- HY-134575
-
|
|
Apoptosis
GSK-3
|
Others
|
|
C24:1-Ceramide is one of the most abundant naturally occurring ceramide. Ceramides regulates many diverse biological activities, such as cell apoptosis, cell differentiation, proliferation of smooth muscle cells, and inhibition of the mitochondrial respiratory chain .
|
-
-
- HY-19542S1
-
|
C6-Cer-d11; N-Hexanoylsphingosine-d11
|
Apoptosis
Isotope-Labeled Compounds
|
Cancer
|
|
C6 Ceramide-d11 is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
|
-
-
- HY-D1582
-
|
|
Fluorescent Dye
|
Others
|
|
C12 NBD Phytoceramide, a ceramide analogue, is a fluorescent substrate, can be used to detect ceramidase activity .
|
-
-
- HY-165099
-
|
|
Apoptosis
PI3K
DNA/RNA Synthesis
|
Metabolic Disease
|
C-8 Ceramide-1-phosphate is a cell apoptosis inhibitor and a cell survival inducer that can stimulate DNA synthesis and cell division. C-8 Ceramide-1-phosphate can inhibit acidic sphingomyelinase (SMase) and stimulate PI3-K, which in turn produces PIP3; PIP3 can also inhibit acidic SMase. The C-8 Ceramide-1-phosphate and ceramide can be interconverted in cells through kinase and phosphatase activity, and maintaining the balance between the two is crucial for cellular and tissue homeostasis .
|
-
-
- HY-D1576
-
|
|
Fluorescent Dye
|
Others
|
|
C6 NBD L-threo-dihydroceramide is a dihydro-ceramide isomer labeled with a fluorescent group C6 nitrobenzoxadiazole (C6 NBD), can be used to detect ceramide.
|
-
-
- HY-E70281
-
|
rEGCase II
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Recombinant endoglycoceramidase II (rEGCase II) is an endo-β-glucosidase releasing the complete glycan from ceramide in glycosphingolipids. Recombinant endoglycoceramidase II catalyzes the hydrolysis of the β-glycosidic linkage between oligosaccharides and ceramides in various glycosphingolipids .
|
-
-
- HY-132182
-
|
|
Others
|
Cancer
|
|
HPA-12 is an intracellular ceramide transport protein inhibitor .
|
-
-
- HY-141575
-
|
|
Fluorescent Dye
|
Others
|
|
C12-NBD-ceramide is a fluorescent analogue of ceramide, it can be used as a substrate in ceramidase assays .
|
-
-
- HY-D2256
-
-
-
- HY-108391
-
|
N-Octanoyl-D-erythro-sphingosine
|
Apoptosis
PKC
Autophagy
|
Inflammation/Immunology
Cancer
|
|
C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro .
|
-
-
- HY-157418
-
|
|
Others
|
Others
|
|
1-Deoxy-Cer is a Ceramide which is essential component of the skin permeability barrier.
|
-
-
- HY-103359
-
|
|
Ceramidase
|
Cancer
|
|
Ceranib1 is a ceramidase inhibitor. Ceranib1 inhibits ceramidase activity toward an exogenous ceramide analog, induces the accumulation of multiple ceramide species, decreases levels of sphingosine and S1P. Ceranib1 inhibits the proliferation of ovarian cancer cells .
|
-
-
- HY-P1975
-
|
Basifungin
|
Fungal
Parasite
|
Infection
Inflammation/Immunology
|
|
Aureobasidin A (Basifungin) is a cyclic peptide antibiotic with oral activity. Aureobasidin A is an inhibitor of inositol phosphorylated ceramide synthetase AUR1. Aureobasidin A has antifungal and antiparasitic activity .
|
-
-
- HY-101180
-
|
Ceramide 2
|
Phosphatase
Mitochondrial Metabolism
Apoptosis
Autophagy
|
Metabolic Disease
Endocrinology
|
|
C2 Ceramide (Ceramide 2) is the main lipid of the stratum corneum and a protein phosphatase 1 (PP1) activator. C2 Ceramide activates PP2A and ceramide-activated protein phosphatase (CAPP). C2 Ceramide induces cells differentiation, autophagy and apoptosis, inhibits mitochondrial respiratory chain complex III. C2 Ceramide is also a skin conditioning agent that protects the epidermal barrier from water loss .
|
-
-
- HY-19542
-
|
C6-Cer; N-Hexanoylsphingosine
|
Apoptosis
|
Cancer
|
|
C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
|
-
-
- HY-D1573
-
|
|
Fluorescent Dye
|
Others
|
|
C6 NBD Phytoceramide is a fluorescently labeled short-chain ceramide analog that can be recognized by mammalian GlcCer synthase (GCS) .
|
-
-
- HY-13626
-
|
ES-285
|
PKC
Apoptosis
|
Cancer
|
|
Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation. Spisulosine induces apoptosis in PC-3 and LNCaP cells .
|
-
-
- HY-P2936
-
|
|
Phospholipase
|
Metabolic Disease
|
|
Sphingomyelin phosphodiesterase, Streptomyces sp., a hydrolase, is involved in the sphingomyelin metabolism process. Sphingomyelin phosphodiesterase hydrolyzes the conversion of sphingomyelin to phosphocholine and ceramide. Sphingomyelin phosphodiesterase also plays an important role in cellular differentiation, various immune and inflammatory responses, and intracellular cholesterol trafficking and metabolism .
|
-
-
- HY-131703
-
|
|
UGT
|
Metabolic Disease
|
|
UGT8-IN-1 is a brain penetrable and orally active inhibitor of ceramide galactosyltransferase enzyme (UGT8). UGT8-IN-1 can be used in the study for lysosomal storage disorders .
|
-
-
- HY-17020
-
-
-
- HY-17020A
-
-
-
- HY-129099
-
|
|
PKC
Estrogen Receptor/ERR
Drug Metabolite
Endogenous Metabolite
|
Cancer
|
|
N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .
|
-
-
- HY-129099A
-
|
|
PKC
Estrogen Receptor/ERR
Drug Metabolite
Endogenous Metabolite
|
Cancer
|
|
N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .
|
-
-
- HY-E70280
-
|
rEGCase I
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Recombinant endoglycoceramidase I (rEGCase I) is a glycosidase that catalyzes the hydrolysis of the β-glycosidic linkage between oligosaccharides and ceramides. Recombinant endoglycoceramidase I catalyzes a transglycosylation reaction, which transfers the sugar moiety of glycosphingolipids (GSLs) to the primary hydroxyl group of several 1-alkanols .
|
-
-
- HY-129099AR
-
|
|
PKC
Estrogen Receptor/ERR
Drug Metabolite
Endogenous Metabolite
|
Cancer
|
|
N-Desmethyltamoxifen (hydrochloride) (Standard) is the analytical standard of N-Desmethyltamoxifen (hydrochloride). This product is intended for research and analytical applications. N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].
|
-
-
- HY-114615
-
-
-
- HY-126015
-
P053
1 Publications Verification
|
Acyltransferase
|
Metabolic Disease
|
|
P053 is a potent, non-competitive and selective ceramide synthase 1 (CerS1) inhibitor wirh an IC50 of 0.5 μM. P053 acts as an endogenous inhibitor of mitochondrial fatty acid oxidation in muscle. Whole-body adiposity regulator .
|
-
-
- HY-166315S
-
-
-
- HY-D1579
-
|
|
Fluorescent Dye
|
Others
|
|
C12 NBD galactosylceramide is a biologically active derivative of galactosylceramide that is tagged with a fluorescent C12 nitrobenzoxadiazole (C12 NBD) group. C12 NBD galactosylceramide has been used to detect ceramide trihexoside .
|
-
-
- HY-100353R
-
|
N-Lauroyl-D-erythro-sphingosine (Standard); N-Laurylsphingosine (Standard)
|
Others
|
Metabolic Disease
Cancer
|
|
C12-Ceramide (Standard) is the analytical standard of C12-Ceramide. This product is intended for research and analytical applications. C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease[1][1].
|
-
-
- HY-100354S3
-
-
-
- HY-100354S4
-
-
-
- HY-100355S1
-
-
-
- HY-116147
-
|
|
LPL Receptor
Apoptosis
|
Cancer
|
|
Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC50 of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P), and induces cell apoptosis. Anticancer activity .
|
-
-
- HY-145467
-
|
C16 Ceramide-1-phosphate ammonium; Ceramide-1-phosphate (d18:1/16:0) ammonium; CerP(d18:1/16:0) ammonium
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
C16 Ceramide-1-phosphate (d18:1/16:0) (ammonium) (C16 Ceramide-1-phosphate (ammonium); Ceramide-1-phosphate (d18:1/16:0) (ammonium)) is an ester product.
|
-
-
- HY-134508
-
|
|
Liposome
|
Others
|
|
C24-Ceramide is a sphingolipid that can be used for the lipid membranes composed. C24-Ceramide induces time-dependent changes in membrane properties. C24-Ceramide induces membrane reorganization .
|
-
-
- HY-100355S
-
-
-
- HY-134508S
-
-
-
- HY-146902S
-
-
-
- HY-100355R
-
|
|
Endogenous Metabolite
|
Neurological Disease
Cancer
|
|
C18-Ceramide (Standard) is the analytical standard of C18-Ceramide. This product is intended for research and analytical applications. C18-Ceramide can promote exocytosis of glutamate from damaged neurons. C18-Ceramide promotes cell death in glioma cells. Ceramides is involved in diverse cellular functions, such as differentiation, cell cycle progression, cell-cell adhesion, senescence, and apoptosis[1].
|
-
-
- HY-154831
-
|
N-Behenoyl-D-erythro-sphingosine; Cer d18:1/22:0
|
Liposome
|
Metabolic Disease
|
|
C22-Ceramide (Cer d18:1/22:0) is an endogenous bioactive sphingolipid. C22-Ceramide reduces the propensity of C16-ceramide channel formation in isolated rat liver mitochondria and in liposomes .
|
-
-
- HY-134575S
-
-
-
- HY-119312
-
|
|
PKC
|
Cancer
|
|
C8 Dihydroceramide is a negative control of C8 Ceramide. C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro .
|
-
-
- HY-141578S
-
-
-
- HY-163472
-
|
|
Stearoyl-CoA Desaturase (SCD)
|
Metabolic Disease
Cancer
|
|
PR280 is a potent inhibitor of dihydroceramide desaturase 1 (Des1) (IC50=700 nM). PR280 forms hydrogen bonds with the amino acid residues of Des1, and its cyclopropenone group may form a coordination with the iron center, thus stabilizing the binding to the active site of Des1 and inhibiting the sphingosine lipid synthesis pathway of dihydroceramide (dhCer) to form ceramide. PR280 can be used in the study of diseases related to sphingosine lipid metabolism, such as cancer and metabolic diseases .
|
-
-
- HY-100353
-
|
N-Lauroyl-D-erythro-sphingosine; N-Laurylsphingosine
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease .
|
-
- HY-158783
-
|
|
Ceramidase
Bcl-2 Family
LPL Receptor
Apoptosis
|
Neurological Disease
|
|
SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a Ki of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models .
|
-
- HY-W698686S
-
|
|
Isotope-Labeled Compounds
Others
|
Others
|
|
β-Galactosyl-C18-ceramide-d35 is deuterium labeled β-Galactosyl-C18-ceramide. β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition .
|
-
- HY-146935S
-
-
- HY-146760S
-
-
- HY-146906S
-
-
- HY-146934S
-
-
- HY-146936S
-
-
- HY-141578S1
-
-
- HY-19542S
-
|
|
Isotope-Labeled Compounds
Apoptosis
|
Cancer
|
|
Ceramide C6-d7 is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells[1][2][3].
|
-
- HY-166262
-
-
- HY-166277
-
-
- HY-166315
-
-
- HY-146907S
-
-
- HY-134508A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
C24-Ceramide (d18:1/24:0) is a sphingolipid that can be used for the lipid membranes composed. C24-Ceramide (d18:1/24:0) induces time-dependent changes in membrane properties. C24-Ceramide (d18:1/24:0) induces membrane reorganization .
|
-
- HY-165781
-
-
- HY-W778830
-
|
|
Drug Metabolite
|
Neurological Disease
|
|
Bodipy C12-ceramide (B12Cer) is a fluorescently tagged form of C12-Ceramide (HY-100353) that displays excitation/emission maxima of 505/540 nm, respectively. Bodipy C12-ceramide is formed when acid sphingomyelinase hydrolyzes BODIPY-C12 sphingomyelin in vitro and has been used to quantify acid sphingomyelinase activity in plasma with Niemann-Pick disease .
|
-
- HY-W698686
-
|
|
Biochemical Assay Reagents
|
|
|
β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition.
|
-
- HY-W654105
-
-
- HY-W588184
-
|
|
Biochemical Assay Reagents
|
Others
|
|
(Rac)-C22-Ceramide is a lipid featuring two hydrophobic tails, one saturated and the other unsaturated. Ceramides may be used in developing lipid nanoparticles or liposomes.
|
-
- HY-147178
-
|
|
Fluorescent Dye
|
Others
|
|
C-6 NBD-dihydro-Ceramide is a membrane-permeable ceramides. C-6 NBD-dihydro-Ceramide is a biologically active fluorescent analog of short chain .
|
-
- HY-112016
-
-
- HY-W590667
-
|
|
Biochemical Assay Reagents
|
Others
|
|
C2 Ceramide-1-phosphate is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations, thereby achieving better therapeutic effects. C2 Ceramide-1-phosphatecan be used in drug delivery research .
|
-
- HY-160410
-
|
|
Others
|
Neurological Disease
Inflammation/Immunology
|
|
Ceramide 3B is a ceramide 3 lipid class with aggregation behavior. Ceramide 3B has a variety of physiological functions and can serve as a penetration enhancer and auxiliary emulsifier, playing an important role in barrier function stability .
|
-
- HY-116258S
-
-
- HY-168762
-
-
- HY-100354
-
-
- HY-116609
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
C6 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides . C6 L-threo Ceramide significantly inhibits IL-4 production in T cells. Anti-allergic agents .
|
-
- HY-100354S
-
-
- HY-W214059S
-
-
- HY-W747533
-
|
C8 Ceramine; Ceramine (d18:1/8:0)
|
Drug Derivative
|
Others
|
|
C8 Ceramine is an analog of ceramide in which the carbonyl group of the ceramide is replaced by a methylene group. At a concentration of 10 μM, C8 ceramine induces maximal DNA fragmentation in U937 cells after 6 hours of incubation, compared to 12 hours for C8 ceramide.
|
-
- HY-W590674
-
|
|
Biochemical Assay Reagents
|
Others
|
|
C26 Ceramide is a lipid featuring two hydrophobic tails, one saturated and the other unsaturated. Ceramides may be used in developing lipid nanoparticles or liposomes.
|
-
- HY-W590573
-
|
|
Biochemical Assay Reagents
|
Others
|
|
C3 Ceramide is a lipid featuring two hydrophobic tails, one saturated and the other unsaturated. Ceramides may be used in developing lipid nanoparticles or liposomes.
|
-
- HY-160850
-
|
|
Endogenous Metabolite
|
Endocrinology
|
|
C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) is a specific type of long-chain molecule found in murine skin . C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) promotes migration of both mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells at concentrations between 0.5-5 µM. C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt)’s levels are higher in CFPAC-1 pancreatic ductal adenocarcinoma cells than in pancreatic cancer stem cells .
|
-
- HY-172000
-
-
- HY-167593S
-
-
- HY-167594S
-
-
- HY-144005B
-
|
C16 PEG Ceramide (MW 5000)
|
Biochemical Assay Reagents
Liposome
|
Others
|
|
C16 PEG5000 Ceramide (C16 PEG Ceramide (MW 5000)) is a PEG lipid for the preparation of liposomes and can be used in drug delivery studies .
|
-
- HY-144008
-
|
|
Liposome
|
Others
|
|
C8 PEG-Ceramide is a lipid product. C8 PEG-Ceramide can synthesize lipid bilayer carrier and can be used for drug delivery .
|
-
- HY-144005A
-
|
C16 PEG Ceramide (MW 750)
|
Biochemical Assay Reagents
Liposome
|
Others
|
|
C16 PEG750 Ceramide (C16 PEG Ceramide (MW 750)) is a PEG lipid for the preparation of liposomes and can be used in drug delivery studies .
|
-
- HY-124177
-
-
- HY-116017
-
-
- HY-139062
-
|
C6 Ceramide (d18:1/6:0) Urea; Cer(d18:1/6:0) Urea; D-erythro-Urea-C6-Ceramide
|
Apoptosis
Ceramidase
Autophagy
β-catenin
|
Cancer
|
|
C6 Urea Ceramide (Cer(d18:1/6:0) Urea) is an inhibitor of neutral ceramidase. C6 Urea Ceramide increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and HT-29 colon cancer cells. C6 Urea Ceramide (5-10 μM) inhibits proliferation of HT-29 cells and induces apoptosis and autophagy, but is not toxic to non-cancerous cells. C6 Urea Ceramide decreases total and phosphorylated β-catenin levels in HT-29 and HCT116 cells, and induces colocalization of β-catenin with the 20S proteasome. C6 Urea Ceramide (1.25, 2.5, and 5 mg/kg) reduced tumor growth and increased C16, C18, C20, and C24 ceramide levels in tumor tissues in the HT-29 mouse xenograft model.
|
-
- HY-144008A
-
|
|
Liposome
|
Others
|
|
C8 PEG5000 Ceramide is a lipid product. C8 PEG5000 Ceramide can synthesize lipid bilayer carrier and can be used for drug delivery .
|
-
- HY-P2982
-
|
|
Liposome
|
Metabolic Disease
|
|
Ceramide 1-phosphate is a bioactive lipid and one of the key components of sphingolipids. Ceramide 1-phosphate playing diverse roles in cellular behaviors such as cell differentiation, migration, proliferation and death .
|
-
- HY-E70023
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Sphingolipid ceramide N-deacylase (SCDase) cleaves the N-acyl linkage between fatty acids and sphingosine bases in various glycosphingolipids. Sphingolipid ceramide N-deacylase catalyzes glycosphingolipids to lysoglycosphingolipids .
|
-
- HY-139404
-
|
Anthrylvinyl ceramide; AV Ceramide; AV Ceramide (d18:1/10:0)
|
Fluorescent Dye
|
Others
|
|
C10 AV Ceramide (d18:1/10:0) is a fluorescent probe. Anthrylvinyl (AV) acts as the fluorescent label positioned on the amide linked acyl chain on the Ceramide molecule to measure the CERT-mediated transfer. The anthrylvinyl moiety of C10 AV Ceramide (d18:1/10:0) localizes to the hydrophobic region of the bilayer .
|
-
- HY-D1612
-
|
|
Fluorescent Dye
|
Others
|
|
The Golgi apparatus is composed of flattened vesicles superimposed on each other by unit membranes. The flattened vesicles are round with expanded and perforated edges. The Golgi fluorescent probe is a BODIPY-labeled ceramide derivative, the synthesis of which occurs in the endoplasmic reticulum and can then be transported to the Golgi via ceramide transport protein (CERT) or vesicular translocation, allowing specific labeling of the dye . BODIPY Fl C5-Ceramide is a Golgi-specific green fluorescent dye, which can visualise individual cells . Ex/Em= 505 nm/512 nm.
|
-
- HY-144008B
-
|
|
Biochemical Assay Reagents
|
Others
|
|
C8 PEG750 Ceramide is a lipid product. C8 PEG750 Ceramide synthesizes a lipid bilayer carrier for the selective delivery of various diagnostic and therapeutic agents to acidic diseased cells .
|
-
- HY-124134
-
|
LCL102
|
Ceramidase
Caspase
PARP
|
Cancer
|
|
AD-2646 (LCL102), a ceramide analog, can kill leukemic T cells (EC50: 40 μM). AD-2646 triggers the cleavage of caspase-8, -9 and -3, as well as the caspase substrate PARP. AD-2646 is a ceramidase inhibitor. AD-2646 induces an accumulation of endogenous ceramide owing to perturbed ceramide metabolism .
|
-
- HY-166305
-
-
- HY-N14939
-
-
- HY-116585
-
|
|
Liposome
Interleukin Related
|
Neurological Disease
|
|
C6 D-Threo Ceramide (d18:1/6:0) is a bioactive sphingolipid and cell-permeable analog of ceramides. C6 D-Threo Ceramide (d18:1/6:0) enhances IL-4 production induced by Phorbol 12-myristate 13-acetate (HY-18739) in EL4 T cells .
|
-
- HY-158873
-
-
- HY-E70038
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Endoglycoceramidase II (EGCase II) is an endo-β-glucosidase releasing the complete glycan from ceramide in glycosphingolipids. Endoglycoceramidase II Catalyzes the hydrolysis of the β-glycosidic linkage between oligosaccharides and ceramides in various glycosphingolipids .
|
-
- HY-W923646
-
-
- HY-145517
-
|
|
Apoptosis
|
Neurological Disease
|
|
C6-Phytoceramide is a cell-permeable analog of Phytoceramide. C6-Phytoceramide induces higher levels of apoptosis than C6-Ceramide (HY-19542) in neuroblastoma cells .
|
-
- HY-D2255
-
|
|
Fluorescent Dye
|
Others
|
|
BDP FL ceramide, a highly fluorescent lipid, is a conjugate of green-emitting BDP FL fluorophore with sphingosine. BDP FL ceramide can be used for the visualization of the Golgi apparatus via fluorescence microscopy.The excitation wavelength is 503 nm and the emission wavelength is 509 nm .
|
-
- HY-165034
-
|
((±)-2'-Hydroxy) cer(d18:1/18:0); 18:0 (2R/S-OH)-Ceramide; ((±)-2'-Hydroxy) ceramide (d18:1/18:0)
|
Endogenous Metabolite
|
Others
|
|
C18 ((±)-2'-Hydroxy) ceramide ((±)-2'-Hydroxy) cer) (d18:1/18:0) is a bioactive sphingolipid found in the stratum corneum layer of mammalian epidermis. Ceramides maintains the normal hydration levels required for the normal physiological .
|
-
- HY-19542A
-
-
- HY-13945
-
NVP 231
3 Publications Verification
|
Apoptosis
|
Cancer
|
|
NVP 231 is a potent, specific, and reversible ceramide kinase (CerK) inhibitor(IC50=12 nM) that competitively inhibits binding of ceramide to CerK . NVP 231 induces cell apoptosis by increasing DNA fragmentation and caspase-3 and caspase-9 cleavage .
|
-
- HY-156206
-
-
- HY-W923636
-
-
- HY-W590666
-
-
- HY-W356116
-
|
Nbd-ceramide
|
Fluorescent Dye
|
Others
|
|
C6 NBD Ceramide is a Golgi apparatus fluorescent probe with cell membrane permeability. C6 NBD Ceramide can be used for fast and convenient green fluorescent labeling of Golgi in living and fixed cells, and can be used to observe changes in Golgi morphology in living cells (Ex=466 nm, Em=536 nm). C6-NBD-ceramide is metabolized to fluorescent sphingomyelin and glucosylceramide, can be used for the study of sphingolipid transport and metabolic mechanism .
|
-
- HY-D1749
-
|
|
Fluorescent Dye
|
Others
|
|
C6 NBD L-threo-ceramide is a cell-permeable analog of ceramides that is tagged with a fluorescent group C6 nitrobenzoxadiazole (C6 NBD). It is rapidly transferred between liposomes, labels the Golgi apparatus, and is metabolized to C6 NBD sphingomyelin in BHK cells and V79 fibroblasts.
|
-
- HY-124273
-
|
L-threo Cer(d18:1/2:0); L-threo Ceramide (d18:1/2:0); N-acetyl-L-threo-Sphingosine
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
C2 L-threo Ceramide (d18:1/2:0) (L-threo Cer(d18:1/2:0); L-threo Ceramide (d18:1/2:0)) is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It stimulates cholesterol efflux in CHO cells expressing the human ABCA1 receptor when used at a concentration of 10 μM, however, this efflux is 50% less than that stimulated by C2 ceramide. C2 L-threo Ceramide inhibits IL-4 production by 17% in EL4 T cells stimulated with phorbol 12-myristate 13-acetate when used at a concentration of 10 μM. It also induces cell cycle arrest in the G0/G1 phase and a 7-fold increase in sphingosine accumulation as well as inhibits growth of HL-60 leukemia cells.
|
-
- HY-167595S
-
-
- HY-131992
-
|
C2 Galactosylceramide (d18:1/2:0)
|
Apoptosis
|
Inflammation/Immunology
|
|
N-Acetylpsychosine (C2 Galactosylceramide (d18:1/2:0)), α-galactosylated C2-ceramide, has immunostimulatory activity. N-Acetylpsychosine can be a useful tool to investigate the mechanism of apoptosis and the immune reponses induced by dendritic cells (DCs) .
|
-
- HY-167596S
-
-
- HY-167598S
-
-
- HY-165087
-
-
- HY-D1735
-
|
Golgi-Red Tracke
|
Fluorescent Dye
|
Others
|
|
The Golgi apparatus is composed of flattened vesicles superimposed on each other by unit membranes. The flattened vesicles are round with expanded and perforated edges. The Golgi fluorescent probe is a BODIPY-labeled ceramide derivative, the synthesis of which occurs in the endoplasmic reticulum and can then be transported to the Golgi via ceramide transport protein (CERT) or vesicular translocation, allowing specific labeling of the dye. BODIPY TR Ceramide (Golgi-Red Tracke) is a Golgi-specific fluorescent dye, which can visualise individual cells . Ex/Em=589 nm/616 nm.
|
-
- HY-117081
-
|
|
Endogenous Metabolite
|
Others
|
|
C30(ω-hydroxy) Ceramide (d18:1/30:0), a sphingolipid, is an epidermis-specifically vital component of the water barrier in mammalian skin. C30(ω-hydroxy) Ceramide (d18:1/30:0) is expressed in epidermal keratinocytes and male germ cells during their differentiation and maturation. C30(ω-hydroxy) Ceramide (d18:1/30:0) deficiency in the epiderm of Elovl4 deletion or mutation mice .
|
-
- HY-167597S
-
-
- HY-165158
-
-
- HY-167599S
-
-
- HY-116877
-
|
|
COX
|
Cancer
|
|
C2 Ceramide (d14:1/2:0) is a composition for diagnosing diseases associated with cyclooxygenase 2 (COX2) overexpression. C2 Ceramide (d14:1/2:0) exhibits a strong binding activity to COX2 protein (extracted from patent WO2019235824A1).
|
-
- HY-158725
-
|
|
Endogenous Metabolite
|
Others
|
|
N-Octadecenoyl-(cis-9) -Sulfatide is a glycolipid found in the brains of mice. N-Octadecenoyl-(cis-9) -Sulfatide can be used as a standard for the determination of C18:13 '-mergogalactosyllactose in dry blood stains of patients with chromatic leukodystrophy (MLD) by ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) .
|
-
- HY-165066
-
-
- HY-165986
-
-
- HY-165064
-
|
L-Erythro cer(d18:1/2:0); N-Acetyl-L-erythro-sphingosine; Acetyl-L-erythro-sphingosine
|
Others
|
Cancer
|
|
C2 L-Erythro ceramide (d18:1/2:0) is a cell-permeable sphingolipid. C2 L-Erythro ceramide (d18:1/2:0) induces cell cycle arrest in the G0/G1 phase and inhibits cell growth .
|
-
- HY-165033
-
|
(2'(R)-Hydroxy) ceramide (d18:1/24:0); 2'(R)-hydroxy cer(d18:1/24:0); 24:0(2R-OH) Ceramide
|
Biochemical Assay Reagents
|
Others
|
|
C24 (2'(R)-Hydroxy) ceramide (d18:1/24:0) is a biochemical reagent.
|
-
- HY-165031
-
|
16:0 (2S-OH)-Ceramide; 2'-Hydroxy C16-ceramide; 2'(S)-Hydroxy cer(d18:1/16:0)
|
Biochemical Assay Reagents
|
Others
|
|
C16 (2'(S)-Hydroxy) ceramide (d18:1/16:0) is a biochemical reagent.
|
-
- HY-165032
-
|
(2'(S)-Hydroxy) ceramide (d18:1/24:0); 2'(S)-Hydroxy cer (d18:1/24:0); 24:0(2S-OH) Ceramide
|
Biochemical Assay Reagents
|
Others
|
|
C24 (2'(S)-Hydroxy) ceramide (d18:1/24:0) is a biochemical reagent.
|
-
- HY-115703
-
-
- HY-116258
-
|
|
Liposome
|
Others
|
|
C16 Ceramide (d16:1,C16:0) is a bioactive sphingolipid that induces ordered- and gel-phase formation and thermal stabilization of palmitoylsphingomyelin-rich domains in palmitoylphosphocholine (POPC) bilayers. C16 Ceramide (d16:1,C16:0) is found in sphingomyelins in human erythrocytes .
|
-
- HY-118358
-
-
- HY-W590672
-
|
|
Biochemical Assay Reagents
|
Others
|
|
C22 Dihydroceramide is a lipid featuring two saturated hydrophobic tails. Ceramides may be used in developing lipid nanoparticles or liposomes.
|
-
- HY-158952
-
|
(R)-2'-Hydroxy cer(d18:0/24:0); (R)-2'-Hydroxy ceramide (d18:0/24:0); N-(R)-α-C24 Dihydro ceramide (d18:0/24:0)
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
C24 (2'(R)-Hydroxy) dihydro ceramide (d18:0/24:0) ((R)-2'-Hydroxy cer(d18:0/24:0)) is the 2R-isomer of a 2’-hydroxylated form of C24 Dihydro ceramide (d18:0/24:0) (HY-156206).
|
-
- HY-W741062
-
|
iso-C17:0; Isoheptadecasphinganine; 15-Methylhexadecasphinganine
|
Bacterial
|
Infection
|
|
Sphinganine (d16:0 branched) is an iso-branched sphingolipid. It has been found as a component of ceramide-containing phospholipids in bacteria.
|
-
- HY-145520
-
-
- HY-167803
-
|
24:1(2R-OH) Ceramide
|
Biochemical Assay Reagents
|
|
|
N-(2'-(R)-Hydroxynervonoyl) -d-erythro-Sphingosine (24:1(2R-OH) Ceramide) is a biochemical reagent .
|
-
- HY-170794
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
ALT-007 is an orally effective serine palmitoyltransferase (SPT) inhibitor. SPT is the rate-limiting enzyme for the de novo synthesis of ceramide. In a mouse model of age-related sarcopenia, ALT-007 can effectively restore the muscle mass and function impaired by aging. ALT-007 may enhance protein homeostasis in Caenorhabditis elegans and mouse models of aging and age-related diseases and play the role of a ceramide inhibitor .
|
-
- HY-144267
-
|
|
Glucosylceramide Synthase (GCS)
|
Neurological Disease
Metabolic Disease
|
|
Glucosylceramide synthase-IN-2 (compound T-690) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 15 nM and 190 nM for human GCS and mouse GCS, respectively.Glucosylceramide synthase-IN-2 exhibits noncompetitive type inhibition with C8-ceramide and UDP-glucose.Glucosylceramide synthase-IN-2 can be used for Gaucher's disease research .
|
-
- HY-N6723
-
|
|
Acyltransferase
|
Infection
|
|
Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .
|
-
- HY-P4154
-
|
ALM-488
|
Fluorescent Dye
|
Neurological Disease
Cancer
|
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
- HY-156800
-
|
|
Phospholipase
|
Others
|
|
PDDC is a compound used to inhibit Alzheimer's disease. It is a nSMase2 inhibitor that can inhibit tau-induced nSMase2 activity and ceramide elevation, and slow the spread of tau in mouse models.
|
-
- HY-116392G
-
|
|
Glucosylceramide Synthase (GCS)
|
Others
|
|
D,L-erythro-PDMP is an erythro isomer of PDMP. D,L-erythro-PDMP causes growth inhibition of cultured rabbit skin fibroblasts. PDMP is an effective inhibitor of UDP-glucose:ceramide glucosyltransferase .
|
-
- HY-12744A
-
|
|
Glucosylceramide Synthase (GCS)
|
Metabolic Disease
|
|
Genz-123346 is a potent, orally available glucosylceramide synthase inhibitor. Genz-123346 blocks the conversion of ceramide to glucosylceramide (GL1) and inhibits GM1 with an IC50 value of 14 nM .
|
-
- HY-12744
-
-
- HY-116392H
-
|
|
Glucosylceramide Synthase (GCS)
|
Others
|
|
D,L-erythro-PDMP hydrochloride is an erythro isomer of PDMP. D,L-erythro-PDMP hydrochloride causes growth inhibition of cultured rabbit skin fibroblasts. PDMP is an effective inhibitor of UDP-glucose:ceramide glucosyltransferase .
|
-
- HY-169795
-
|
|
Apoptosis
|
Cancer
|
|
C8 D-threo Ceramide (d18:1/8:0) is a sphingolipid analog that can effectively induce apoptosis in U937 cells and cause fragmentation of nucleosomal DNA .
|
-
- HY-W590539
-
|
|
Bacterial
|
Infection
|
|
ω-azido-C6 Ceramide reduces the membrane potential, and exhibits antibacterial activity against Neisseria, with MIC of 2 µg/ml for N. meningitidis MC58 and N. gonorrhoeae FA1090 .
|
-
- HY-N10634
-
|
C16 Glucosyl(β) Ceramide (d18:1/16:0)
|
Others
|
Inflammation/Immunology
|
|
D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity .
|
-
- HY-P1103
-
|
|
CXCR
|
Cancer
|
|
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
- HY-P1103A
-
|
|
CXCR
|
Cancer
|
|
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
- HY-N6730
-
|
Aminopentol
|
Apoptosis
|
Neurological Disease
|
|
Hydrolyzed Fumonisin B1 (Aminopentol) is the backbone and main hydrolysis product of the mycotoxin Fumonisin B1 (HY-N6719). Hydrolyzed Fumonisin B1 can weakly inhibit ceramide synthase .
|
-
- HY-157718
-
|
|
Biochemical Assay Reagents
|
|
|
1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine is a surfactant that has the activity of promoting liposome formation. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine can effectively study the biological effects of ceramide and ceramide phosphate. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine shows important application in the determination of phospholipase A activity of lecithin-cholesterol acyltransferase in ether matrix.
|
-
- HY-W590664
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
C2 Dihydroceramide is a derivative of C2 Ceramide (HY-101180). C2 Dihydroceramide enhances the ABCA1-mediated cholesterol efflux to apolipoprotein A-I (apoA-I) without causing cytotoxicity .
|
-
- HY-P2231A
-
|
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-124962
-
|
(1R,2R)-B13
|
iGluR
|
Neurological Disease
Cancer
|
|
D-NMAPPD ((1R,2R)-B13) is an acid ceramidase inhibitor. D-NMAPPD regulates NMDA receptor properties by enhancing endogenous production of ceramides. D-NMAPPD has anticancer effecs .
|
-
- HY-141630
-
|
D-erythro-Sphingosine-C17-1-phosphate
|
Drug Derivative
|
Cancer
|
|
Sphingosine-1-phosphate d17:1 (D-erythro-Sphingosine-C17-1-phosphate) is a derivative of ceramide. Sphingosine-1-phosphate d17:1 can be used for the research of cancer .
|
-
- HY-N6719
-
|
|
Acyltransferase
|
Infection
|
|
Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .
|
-
- HY-115737
-
|
|
Apoptosis
|
Cancer
|
|
L-threo-PPMP is a GlcT (UDP-Glc: Ceramide β1,1glucosyltransferase) inhibitor. L-threo-PPMP inhibits glycosphingolipid biosynthesis and induces apoptosis. L-threo-PPMP has anti-cancer activity .
|
-
- HY-W356117
-
|
|
Fluorescent Dye
|
Others
|
|
C6 NBD Glucosylceramide is a glucosylceramide fluorescent derivative (Ex=466 nm, Em=535 nm). C6 NBD Glucosylceramide can be used to study the metabolism and internalization of glucosylceramide and also for the determination of glucosyl ceramide synthase activity .
|
-
- HY-155111
-
|
|
Phospholipase
|
Neurological Disease
|
|
nSMase2-IN-1 is an orally active Neutral sphingomyelinase 2 (nSMase2) inhibitor with an IC50 value of 0.13 ± 0.06 μM. nSMase2-IN-1 is metabolically stable in liver microsomes and orally available with a favorable brain-to-plasma ratio. nSMase2-IN-1 can be used for nervous system disease research .
|
-
- HY-170035
-
|
C18 Glucosyl(β) ceramide (d18:1/18:0); D-glucosyl-β-1,1' N-stearoyl-D-erythro-sphingosine
|
Liposome
|
Neurological Disease
|
|
GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipid. GlcCer (d18:1/18:0) is promising for research of Parkinson disease and dementia with Lewy bodies .
|
-
- HY-124758
-
|
|
Mitochondrial Metabolism
|
Metabolic Disease
Cancer
|
|
SH-BC-893 is an orally active anti-neoplastic sphingolipid analog. SH-BC-893 also protects from ceramide-induced mitochondrial dysfunction and corrects diet-induced obesity. SH-BC-893 can be used for the research of cancer and obesity .
|
-
- HY-P10026
-
-
- HY-P4757
-
|
|
Parasite
|
Others
|
|
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
|
-
- HY-P2231
-
|
MEDI0382
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-E70288
-
|
ST6GALNAC6
|
Others
|
Inflammation/Immunology
|
|
ST6 Sialyltransferase 6 (ST6GALNAC6) belongs to the salivary transferase family, which modifies proteins and ceramides on the cell surface, thereby altering intercellular or extracellular matrix interactions. ST6 Sialyltransferase 6 can be used in the study of inflammatory bowel disease (IBD) .
|
-
- HY-141866
-
|
|
Ceramidase
|
Neurological Disease
|
|
Acid Ceramidase-IN-1 is a potent and oral bioavailable acid ceramidase (AC, ASAH-1) inhibitor (hAC IC50=0.166 μM). Acid Ceramidase-IN-1 has excellent brain penetration in mice .
|
-
- HY-125407
-
|
N-Palmitoyl serinol
|
Cannabinoid Receptor
|
Inflammation/Immunology
|
|
Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin .
|
-
- HY-149120
-
|
|
Phospholipase
|
Cardiovascular Disease
Inflammation/Immunology
|
|
ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity .
|
-
- HY-157343A
-
|
|
Apoptosis
|
Neurological Disease
Cancer
|
|
GD3 Ganglioside sodium is a prominent ganglioside of human melanoma. GD3 Ganglioside sodium is an inducer of mitochondrial permeability. GD3 ganglioside directly targets mitochondria in a bcl-2-controlled fashion. GD3 ganglioside is rapidly synthesized from accumulated ceramide after the clustering of death-inducing receptors and triggers apoptosis .
|
-
- HY-N6723S
-
|
|
Isotope-Labeled Compounds
|
Infection
|
|
Fumonisin B2- 13C34 is the 13C labeled Fumonisin B2 (HY-N6723) . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .
|
-
- HY-D1574
-
|
|
Fluorescent Dye
|
Others
|
|
C6 NBD Sphingomyelin is a fluorescent short-chain analogue of Sphingomyelin (HY-113498). Chlamydia trachomatis acquires C6 NBD Sphingomyelin endogenously synthesizes from C6-NBD-ceramide and transportes to the chlamydial inclusion. C6 NBD Sphingomyelin can incorporate into the plasma membrane .
|
-
- HY-122788
-
|
Oleoyl serinol
|
Apoptosis
|
Cancer
|
|
N-Oleoyl serinol is a ceramide analog that can be used in stem cell therapy to prevent stem cells from developing into teratomas. N-Oleoyl serinol induces apoptosis in residual pluripotent embryoid body-derived cells (EBCs), prevents teratoma formation, and enriches EBC cells that undergo neural differentiation after transplantation .
|
-
- HY-157343
-
|
|
Apoptosis
|
Neurological Disease
Cancer
|
|
GD3 Ganglioside is a prominent ganglioside of human melanoma. GD3 Ganglioside is an inducer of mitochondrial permeability. GD3 ganglioside directly targets mitochondria in a bcl-2-controlled fashion. GD3 ganglioside is rapidly synthesized from accumulated ceramide after the clustering of death-inducing receptors and triggers apoptosis .
|
-
- HY-100355
-
|
|
Endogenous Metabolite
|
Neurological Disease
Cancer
|
|
C18-Ceramide is a bioactive molecule with multiple functions in cells, can cross the blood-brain barrier, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology .
|
-
- HY-124042
-
K6PC-5
1 Publications Verification
|
SphK
Filovirus
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
K6PC-5, a ceramide derivative, is a sphingosine kinase 1(SPHK1) activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research .
|
-
- HY-162613
-
|
|
Phospholipase
|
Neurological Disease
|
ASM-IN-2 (Compound 46) is a potent ASM inhibitor with an IC50 value of 0.87 μM, displaying good drug-like properties. ASM-IN-2 involves in multiple antidepressant mechanisms of actionin, which are associated with a decline of ceramide. It demostrates remarkable antidepressant effects in the CUMS-induced mouse, which is promising for research in the field of antidepressant drugs .
|
-
- HY-P1321
-
|
1229U91; GW1229
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
|
-
- HY-P1321A
-
|
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
|
-
- HY-N6719S
-
|
|
Isotope-Labeled Compounds
|
Infection
|
|
Fumonisin B1- 13C34 is the 13C labeled Fumonisin B1 (HY-N6719) . Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .
|
-
- HY-13626S
-
|
ES-285-d3
|
Isotope-Labeled Compounds
PKC
Apoptosis
|
Cancer
|
|
Spisulosine-d3 (ES-285-d3) is deuterium labeled Spisulosine (HY-13626). Spisulosine is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation. Spisulosine induces apoptosis in PC-3 and LNCaP cells .
|
-
- HY-141582S
-
|
N-Stearoyl phytosphingosine-d3
|
Isotope-Labeled Compounds
Biochemical Assay Reagents
|
Others
|
|
Ceramide 3-d3 (N-Stearoyl phytosphingosine-d3) is deuterium labeled Ceramide 3. C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation .
|
-
- HY-131701
-
|
C18 Lactosyl(β) Ceramide; Lactosyl Sphingosine; Lyso-Lactosylceramide (synthetic)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Lactosyl-C18-sphingosine (C18 Lactosyl(β) Ceramide; Lactosyl Sphingosine) is a bioactive sphingolipid that is a form of lactosylceramide but lacks the fatty acyl group. Lysolactosylceramide (1-50 μM) reduces the viability of human neutrophils in a concentration-dependent manner. Unlike lactosylceramide, Lactosyl-C18-sphingosine has no effect on protein synthesis and cell proliferation in cardiomyocytes. Lactosyl-C18-sphingosine is a lysoganglioside GM3.
|
-
- HY-N10634S
-
|
N-ω-CD3-Hexadecaoyl-glucopsychosie; GluCe(d18:1/16:0-d3); Glucosylceamide-d3 (d18:1/16:0-d3)
|
Isotope-Labeled Compounds
Others
|
Inflammation/Immunology
|
|
D-Glucosyl-β-N-palmitoylsphingosine-d3 (N-ω-Cd3-Hexadecaoyl-glucopsychosie) is deuterium labeled D-Glucosyl-β-1,1′-N-palmitoylsphingosine. D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity .
|
-
- HY-117057
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Very long chain polyunsaturated fatty acids (VLCPUFAs) are important components of ceramides and sphingomyelin and are present in retina, sperm, and brain. Tetratriaconta-16(Z),19(Z),22(Z),25(Z),28(Z),31(Z)-hexaenoic acid is a C34:6 VLCPUFA whose specific biological actions are largely unknown. This VLCPUFA, along with others, has been investigated for its role in activating protein kinase C.
|
-
- HY-117057S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
Hexaenoic acid-d6 is deuterium labeled Hexaenoic acid. Very long chain polyunsaturated fatty acids (VLCPUFAs) are important components of ceramides and sphingomyelin and are present in retina, sperm, and brain. Tetratriaconta-16(Z),19(Z),22(Z),25(Z),28(Z),31(Z)-hexaenoic acid is a C34:6 VLCPUFA whose specific biological actions are largely unknown. This VLCPUFA, along with others, has been investigated for its role in activating protein kinase C .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D1612
-
|
|
Fluorescent Dyes/Probes
|
|
The Golgi apparatus is composed of flattened vesicles superimposed on each other by unit membranes. The flattened vesicles are round with expanded and perforated edges. The Golgi fluorescent probe is a BODIPY-labeled ceramide derivative, the synthesis of which occurs in the endoplasmic reticulum and can then be transported to the Golgi via ceramide transport protein (CERT) or vesicular translocation, allowing specific labeling of the dye . BODIPY Fl C5-Ceramide is a Golgi-specific green fluorescent dye, which can visualise individual cells . Ex/Em= 505 nm/512 nm.
|
-
- HY-W356116
-
|
Nbd-ceramide
|
Dyes
|
|
C6 NBD Ceramide is a Golgi apparatus fluorescent probe with cell membrane permeability. C6 NBD Ceramide can be used for fast and convenient green fluorescent labeling of Golgi in living and fixed cells, and can be used to observe changes in Golgi morphology in living cells (Ex=466 nm, Em=536 nm). C6-NBD-ceramide is metabolized to fluorescent sphingomyelin and glucosylceramide, can be used for the study of sphingolipid transport and metabolic mechanism .
|
-
- HY-D1735
-
|
Golgi-Red Tracke
|
Fluorescent Dyes/Probes
|
|
The Golgi apparatus is composed of flattened vesicles superimposed on each other by unit membranes. The flattened vesicles are round with expanded and perforated edges. The Golgi fluorescent probe is a BODIPY-labeled ceramide derivative, the synthesis of which occurs in the endoplasmic reticulum and can then be transported to the Golgi via ceramide transport protein (CERT) or vesicular translocation, allowing specific labeling of the dye. BODIPY TR Ceramide (Golgi-Red Tracke) is a Golgi-specific fluorescent dye, which can visualise individual cells . Ex/Em=589 nm/616 nm.
|
-
- HY-D1582
-
|
|
Chromogenic Substrates
|
|
C12 NBD Phytoceramide, a ceramide analogue, is a fluorescent substrate, can be used to detect ceramidase activity .
|
-
- HY-141575
-
|
|
Fluorescent Dyes/Probes
|
|
C12-NBD-ceramide is a fluorescent analogue of ceramide, it can be used as a substrate in ceramidase assays .
|
-
- HY-D2256
-
|
|
Fluorescent Dyes/Probes
|
|
BDP TMR ceramide is a BDP TMR (a water-soluble dye with a high affinity to lipid bilayers) labeled ceramide. Ex: 542 nm, Em: 572 nm .
|
-
- HY-D1573
-
|
|
Fluorescent Dyes/Probes
|
|
C6 NBD Phytoceramide is a fluorescently labeled short-chain ceramide analog that can be recognized by mammalian GlcCer synthase (GCS) .
|
-
- HY-D1579
-
|
|
Fluorescent Dyes/Probes
|
|
C12 NBD galactosylceramide is a biologically active derivative of galactosylceramide that is tagged with a fluorescent C12 nitrobenzoxadiazole (C12 NBD) group. C12 NBD galactosylceramide has been used to detect ceramide trihexoside .
|
-
- HY-D2255
-
|
|
Fluorescent Dyes/Probes
|
|
BDP FL ceramide, a highly fluorescent lipid, is a conjugate of green-emitting BDP FL fluorophore with sphingosine. BDP FL ceramide can be used for the visualization of the Golgi apparatus via fluorescence microscopy.The excitation wavelength is 503 nm and the emission wavelength is 509 nm .
|
-
- HY-D1749
-
|
|
Fluorescent Dyes/Probes
|
|
C6 NBD L-threo-ceramide is a cell-permeable analog of ceramides that is tagged with a fluorescent group C6 nitrobenzoxadiazole (C6 NBD). It is rapidly transferred between liposomes, labels the Golgi apparatus, and is metabolized to C6 NBD sphingomyelin in BHK cells and V79 fibroblasts.
|
-
- HY-W356117
-
|
|
Fluorescent Dyes/Probes
|
|
C6 NBD Glucosylceramide is a glucosylceramide fluorescent derivative (Ex=466 nm, Em=535 nm). C6 NBD Glucosylceramide can be used to study the metabolism and internalization of glucosylceramide and also for the determination of glucosyl ceramide synthase activity .
|
-
- HY-D1574
-
|
|
Fluorescent Dyes/Probes
|
|
C6 NBD Sphingomyelin is a fluorescent short-chain analogue of Sphingomyelin (HY-113498). Chlamydia trachomatis acquires C6 NBD Sphingomyelin endogenously synthesizes from C6-NBD-ceramide and transportes to the chlamydial inclusion. C6 NBD Sphingomyelin can incorporate into the plasma membrane .
|
| Cat. No. |
Product Name |
Type |
-
- HY-144005
-
|
C16 PEG Ceramide (MW 2000)
|
Drug Delivery
|
|
C16 PEG2000 Ceramide is a polyethylene glycolylated ceramide. C16 PEG2000 Ceramide can be used for lipid carrier to delivery. C16 PEG2000 Ceramide induces autophagy. C16 PEG2000 Ceramide can be used for cancer research .
|
-
- HY-134508
-
|
|
Drug Delivery
|
|
C24-Ceramide is a sphingolipid that can be used for the lipid membranes composed. C24-Ceramide induces time-dependent changes in membrane properties. C24-Ceramide induces membrane reorganization .
|
-
- HY-154831
-
|
N-Behenoyl-D-erythro-sphingosine; Cer d18:1/22:0
|
Drug Delivery
|
|
C22-Ceramide (Cer d18:1/22:0) is an endogenous bioactive sphingolipid. C22-Ceramide reduces the propensity of C16-ceramide channel formation in isolated rat liver mitochondria and in liposomes .
|
-
- HY-165099
-
|
|
Drug Delivery
|
C-8 Ceramide-1-phosphate is a cell apoptosis inhibitor and a cell survival inducer that can stimulate DNA synthesis and cell division. C-8 Ceramide-1-phosphate can inhibit acidic sphingomyelinase (SMase) and stimulate PI3-K, which in turn produces PIP3; PIP3 can also inhibit acidic SMase. The C-8 Ceramide-1-phosphate and ceramide can be interconverted in cells through kinase and phosphatase activity, and maintaining the balance between the two is crucial for cellular and tissue homeostasis .
|
-
- HY-W698686
-
|
|
Cell Assay Reagents
|
|
β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition.
|
-
- HY-W590667
-
|
|
Drug Delivery
|
|
C2 Ceramide-1-phosphate is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations, thereby achieving better therapeutic effects. C2 Ceramide-1-phosphatecan be used in drug delivery research .
|
-
- HY-144005B
-
|
C16 PEG Ceramide (MW 5000)
|
Drug Delivery
|
|
C16 PEG5000 Ceramide (C16 PEG Ceramide (MW 5000)) is a PEG lipid for the preparation of liposomes and can be used in drug delivery studies .
|
-
- HY-144008
-
|
|
Drug Delivery
|
|
C8 PEG-Ceramide is a lipid product. C8 PEG-Ceramide can synthesize lipid bilayer carrier and can be used for drug delivery .
|
-
- HY-144005A
-
|
C16 PEG Ceramide (MW 750)
|
Drug Delivery
|
|
C16 PEG750 Ceramide (C16 PEG Ceramide (MW 750)) is a PEG lipid for the preparation of liposomes and can be used in drug delivery studies .
|
-
- HY-144008A
-
|
|
Drug Delivery
|
|
C8 PEG5000 Ceramide is a lipid product. C8 PEG5000 Ceramide can synthesize lipid bilayer carrier and can be used for drug delivery .
|
-
- HY-167803
-
|
24:1(2R-OH) Ceramide
|
Drug Delivery
|
|
N-(2'-(R)-Hydroxynervonoyl) -d-erythro-Sphingosine (24:1(2R-OH) Ceramide) is a biochemical reagent .
|
-
- HY-157718
-
|
|
Drug Delivery
|
|
1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine is a surfactant that has the activity of promoting liposome formation. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine can effectively study the biological effects of ceramide and ceramide phosphate. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine shows important application in the determination of phospholipase A activity of lecithin-cholesterol acyltransferase in ether matrix.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1975
-
|
Basifungin
|
Fungal
Parasite
|
Infection
Inflammation/Immunology
|
|
Aureobasidin A (Basifungin) is a cyclic peptide antibiotic with oral activity. Aureobasidin A is an inhibitor of inositol phosphorylated ceramide synthetase AUR1. Aureobasidin A has antifungal and antiparasitic activity .
|
-
- HY-P4154
-
|
ALM-488
|
Fluorescent Dye
|
Neurological Disease
Cancer
|
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
- HY-P1103
-
|
|
CXCR
|
Cancer
|
|
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
- HY-P2231A
-
|
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P10026
-
-
- HY-P2231
-
|
MEDI0382
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P1103A
-
|
|
CXCR
|
Cancer
|
|
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
- HY-P4757
-
|
|
Parasite
|
Others
|
|
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
|
-
- HY-P1321
-
|
1229U91; GW1229
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
|
-
- HY-P1321A
-
|
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
|
-
- HY-P4070
-
|
|
Peptides
|
Metabolic Disease
|
|
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec can be used for the research of type 2 diabetes .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-141578
-
-
-
- HY-P1975
-
-
-
- HY-13626
-
-
-
- HY-129099A
-
-
-
- HY-112016
-
-
-
- HY-100354
-
-
-
- HY-129099
-
-
-
- HY-129099AR
-
-
-
- HY-100355R
-
-
-
- HY-N14939
-
-
-
- HY-117081
-
-
-
- HY-145520
-
-
-
- HY-N6723
-
-
-
- HY-N10634
-
-
-
- HY-N6730
-
-
-
- HY-N6719
-
-
-
- HY-100355
-
|
|
Structural Classification
Alkaloids
Neurological Disease
Classification of Application Fields
Other Alkaloids
Source classification
Endogenous metabolite
Disease Research Fields
Cancer
|
Endogenous Metabolite
|
|
C18-Ceramide is a bioactive molecule with multiple functions in cells, can cross the blood-brain barrier, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-100354S3
-
|
|
|
C16-Ceramide-d9 is deuterium labeled C16-Ceramide.
|
-
-
- HY-100354S4
-
|
|
|
C16-Ceramide-d31 is deuterium labeled C16-Ceramide.
|
-
-
- HY-100355S1
-
|
|
|
C18-Ceramide-d7 is deuterium labeled C18-Ceramide.
|
-
-
- HY-134575S
-
|
|
|
C24:1-Ceramide-d7 is the deuterium labeled C24:1-Ceramide[1].
|
-
-
- HY-141578S
-
|
|
|
C18:1-Ceramide- 13C18 is a 13C-labeled C16-Ceramide[1].
|
-
-
- HY-19542S1
-
|
|
|
C6 Ceramide-d11 is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
|
-
-
- HY-166315S
-
|
|
|
C15-Ceramide-d7 is deuterium labeled C15-Ceramide. C15-Ceramide is an ester product .
|
-
-
- HY-100355S
-
|
|
|
C18-Ceramide-d3 is the deuterium labeled C18-Ceramide[1].
|
-
-
- HY-134508S
-
|
|
|
C24-Ceramide-d7 is the deuterium labeled C24-Ceramide[1].
|
-
-
- HY-146902S
-
|
|
|
C15 Ceramide-1-phosphate-d7 is deuterium labeled C15 Ceramide-1-phosphate.
|
-
-
- HY-W698686S
-
|
|
|
β-Galactosyl-C18-ceramide-d35 is deuterium labeled β-Galactosyl-C18-ceramide. β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition .
|
-
-
- HY-146935S
-
|
|
|
C20:1 Ceramide-d7 is deuterium labeled C20:1 Ceramide.
|
-
-
- HY-146760S
-
|
|
|
C15 Glucosyl(β) ceramide-d7 is deuterium labeled C15 Glucosyl(β) ceramide.
|
-
-
- HY-146906S
-
|
|
|
C18 Glucosyl(ß) ceramide-d5 is deuterium labeled C18 Glucosyl(ß) ceramide.
|
-
-
- HY-146934S
-
|
|
|
C22:1 Ceramide-d7 is deuterium labeled C22:1 Ceramide.
|
-
-
- HY-146936S
-
|
|
|
C16:1 Ceramide-d7 is deuterium labeled C16:1 Ceramide.
|
-
-
- HY-141578S1
-
|
|
|
C18:1 Ceramide-d7 is deuterium labeled C18:1 Ceramide.
|
-
-
- HY-19542S
-
|
|
|
Ceramide C6-d7 is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells[1][2][3].
|
-
-
- HY-146907S
-
|
|
|
C18:1 Glucosyl ceramide-d5 is deuterium labeled C18:1 Glucosyl ceramide.
|
-
-
- HY-W654105
-
|
|
|
C18-Ceramide-13C2,d2 is a deuterated labeled C18-Ceramide-13C2,d2 .
|
-
-
- HY-116258S
-
|
|
|
C16 Ceramide-d7 (d16:1,C16:0) is the deuterium labeled C16 Ceramide (d16:1,C16:0)[1].
|
-
-
- HY-100354S
-
|
|
|
C16-Ceramide- 13C16 is a 13C-labeled Glycine ethyl ester monohydrochloride[1].
|
-
-
- HY-W214059S
-
|
|
|
N-Acetyl-S-methyl-L-cysteine-d3 is the deuterium labeled C18:1-Ceramide[1].
|
-
-
- HY-167593S
-
|
|
|
C18:0-d7 GM1 Ceramide is deuterium labeled C18:0 GM1 Ceramide .
|
-
-
- HY-167594S
-
|
|
|
C18:0-d7 GM2 Ceramide is deuterium labeled C18:0 GM2 Ceramide .
|
-
-
- HY-167595S
-
|
|
|
C18:0-d7 GD3 Ceramide (d18:1/18:0-d7) is deuterium labeled C18:0 GD3 Ceramide (d18:1/18:0) .
|
-
-
- HY-167596S
-
|
|
|
C18:0-d7 GD2 Ceramide (d18:1/18:0-d7) is deuterium labeled C18:0 GD2 Ceramide (d18:1/18:0) .
|
-
-
- HY-167598S
-
|
|
|
C18:0-d7 GB4 Ceramide (d18:1/18:0-d7) is deuterium labeled C18:0 GB4 Ceramide (d18:1/18:0) .
|
-
-
- HY-167597S
-
|
|
|
C18:0-d7 GD1b Ceramide (d18:1/18:0-d7) is deuterium labeled C18:0 GD1b Ceramide (d18:1/18:0) .
|
-
-
- HY-167599S
-
|
|
|
C18:0-d7 Fuc-GM1 Ceramide (d18:1/18:0-d7) is deuterium labeled C18:0 Fuc-GM1 Ceramide (d18:1/18:0) .
|
-
-
- HY-N6723S
-
|
|
|
Fumonisin B2- 13C34 is the 13C labeled Fumonisin B2 (HY-N6723) . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .
|
-
-
- HY-N6719S
-
|
|
|
Fumonisin B1- 13C34 is the 13C labeled Fumonisin B1 (HY-N6719) . Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .
|
-
-
- HY-13626S
-
|
|
|
Spisulosine-d3 (ES-285-d3) is deuterium labeled Spisulosine (HY-13626). Spisulosine is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation. Spisulosine induces apoptosis in PC-3 and LNCaP cells .
|
-
-
- HY-141582S
-
|
|
|
Ceramide 3-d3 (N-Stearoyl phytosphingosine-d3) is deuterium labeled Ceramide 3. C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation .
|
-
-
- HY-N10634S
-
|
|
|
D-Glucosyl-β-N-palmitoylsphingosine-d3 (N-ω-Cd3-Hexadecaoyl-glucopsychosie) is deuterium labeled D-Glucosyl-β-1,1′-N-palmitoylsphingosine. D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity .
|
-
-
- HY-117057S
-
|
|
|
Hexaenoic acid-d6 is deuterium labeled Hexaenoic acid. Very long chain polyunsaturated fatty acids (VLCPUFAs) are important components of ceramides and sphingomyelin and are present in retina, sperm, and brain. Tetratriaconta-16(Z),19(Z),22(Z),25(Z),28(Z),31(Z)-hexaenoic acid is a C34:6 VLCPUFA whose specific biological actions are largely unknown. This VLCPUFA, along with others, has been investigated for its role in activating protein kinase C .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-144005
-
|
C16 PEG Ceramide (MW 2000)
|
|
Pegylated Lipids
|
|
C16 PEG2000 Ceramide is a polyethylene glycolylated ceramide. C16 PEG2000 Ceramide can be used for lipid carrier to delivery. C16 PEG2000 Ceramide induces autophagy. C16 PEG2000 Ceramide can be used for cancer research .
|
-
- HY-134508
-
|
|
|
Phospholipids
|
|
C24-Ceramide is a sphingolipid that can be used for the lipid membranes composed. C24-Ceramide induces time-dependent changes in membrane properties. C24-Ceramide induces membrane reorganization .
|
-
- HY-144008
-
|
|
|
Pegylated Lipids
|
|
C8 PEG-Ceramide is a lipid product. C8 PEG-Ceramide can synthesize lipid bilayer carrier and can be used for drug delivery .
|
-
- HY-144008A
-
|
|
|
Pegylated Lipids
|
|
C8 PEG5000 Ceramide is a lipid product. C8 PEG5000 Ceramide can synthesize lipid bilayer carrier and can be used for drug delivery .
|
-
- HY-157718
-
|
|
|
Phospholipids
|
|
1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine is a surfactant that has the activity of promoting liposome formation. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine can effectively study the biological effects of ceramide and ceramide phosphate. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine shows important application in the determination of phospholipase A activity of lecithin-cholesterol acyltransferase in ether matrix.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
